Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus Raltitrexed in Advanced Colorectal Cancer
NCT05426811Phase 2Not yet recruiting
- Sponsor
- China Medical University
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and raltitrexed in colorectal cancer (metastatic) (mCRC), sponsored by China Medical University. Primary endpoint: Progression-free Survival at 1 year. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
regorafenibraltitrexed
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05426811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426811.